Abstract
We evaluated the new 2.0 version of the Roche Diagnostics SARS-CoV-2 Rapid Antigen Test (RAT 2.0) for the detection of SARS-CoV-2. Our evaluation material comprised of nasopharyngeal samples of 140 persons positive for SARS-CoV-2 nucleic acid amplification test (NAAT) and of 100 persons negative for SARS-CoV-2 NAAT. The sensitivity limit of the RAT 2.0 was further estimated with the additional selected samples of 27 persons with high NAAT cycle threshold (Ct) value representing low viral load. For the detection of possible cross-reactions in the RAT 2.0, routine respiratory samples positive for influenza A (N = 5), respiratory syncytial virus (RSV) (N = 4), or combined RSV and human coronavirus OC43 (N = 1) were included in the study material. The overall sensitivity of the RAT 2.0 was 92.1% and specificity 100%. When evaluating the samples with NAAT Ct value ≤ 30, the sensitivity was 97.0%. All samples for cross-reactivity testing containing other viruses instead of SARS-CoV-2 remained negative in RAT 2.0. According to our findings, this RAT 2.0 offers a reliable tool for the diagnostics of acute COVID-19 in this pandemic environment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
